Applications of Gatifloxacin Hydrochloride in Industrial Manufacturing

Gatifloxacin Hydrochloride functions as a high-purity fluoroquinolone antibacterial agent, enabling specialized downstream usage in regulated pharmaceutical and veterinary manufacturing environments. As an original manufacturer, we support B2B application development across multiple advanced processing chains with clear compliance and precise technical requirements.

1. Sterile Solution Injectable Antibacterials

Pharmaceutical formulation plants use Gatifloxacin Hydrochloride as the active pharmaceutical ingredient for compounded sterile parenteral solutions targeting severe gram-negative infections. The API undergoes high-shear dispersion and subsequent sterile filtration under laminar flow before aseptic filling, with process controls focused on minimizing particulate, residual solvent, and bioburden as per strict regulatory expectations for critical care drugs.

Industry compliance standards

• USP and EP monographs for Gatifloxacin injection
• 21 CFR 314 (FDA regulations for parenteral drugs)
• ICH Q7 GMP guidelines for active pharmaceutical ingredients
• Good Distribution Practice (GDP) for cold chain logistics

Typical usage ratio

• Range: 2–4 mg/mL in aqueous parenteral solution
• Ratio adjusted based on dosing per label and patient group
• Excipient ratio coordinated to achieve pH 5–6 and osmolarity consistency
• Final sterile solution concentration varies by therapy protocol

Downstream process integration

• API solubilized in high-purity water under controlled agitation
• Inline sterile filtration (0.22 μm) after pH adjustment
• Aseptic filling into depyrogenated vials in classified cleanroom
• Terminal sterilization and packaging validation per batch

Final product types

• Hospital-use gatifloxacin injection ampoules
• Ready-to-use prefilled syringes
• Bulk sterile concentrate for IV admixture
• Unit-dose vials for pharmacy compounding

2. Oral Solid Tablet Formulation Manufacturing

Commercial oral dosage producers incorporate this fluoroquinolone into film-coated tablets granulated via high-shear or wet granulation. Consistent particle size distribution and chemical stability are critical during blending, compression, and subsequent coating. The downstream workflow includes blend uniformity testing, integration with compatible disintegrants, and controlled environment drying to meet all pharmacopoeial content uniformity requirements.

Industry compliance standards

• US FDA cGMP regulations (21 CFR Part 210/211)
• WHO GMP for solid oral dosage forms
• ICH Q3A/B for impurities and degradation products
• Chinese Pharmacopoeia (if exported to China)

Typical usage ratio

• 200–400 mg API per tablet per final strength
• Adjustments for pediatric vs adult formulations
• API portion 5–35% of total tablet blend, depending on target strength
• Granulation scaling for large-batch commercial lines

Downstream process integration

• Direct blending with inert fillers and controlled sieve size
• Granulation under dehumidified conditions if necessary
• Tablet compression monitored for hardness and friability
• Application of protective film coat to enhance shelf-life

Final product types

• Prescription gatifloxacin tablets
• Repackaged single-dose blisters
• Multi-tablet HDPE bottles for hospitals and clinics
• Hospital formulary stock for community health programs

3. Ophthalmic Solution (Eye Drop) Manufacturing

Specialist manufacturers for sterile ophthalmic preparations solubilize this API using isotonic aqueous vehicles, stabilizers, and pH adjusters designed to limit ocular irritation. The compounding process demands strict microbial and endotoxin control, with the raw material deployed at low concentrations to balance therapeutic efficacy and minimization of local tissue sensitivity. Every batch undergoes particulate, sterility, and preservative system validation prior to filling in single-dose dropper formats.

Industry compliance standards

• USP <797> for pharmaceutical compounding – sterile preparations
• FDA Guidance for Industry: Ophthalmic Drug Products – Quality Considerations
• Ph. Eur. monograph for gatifloxacin ophthalmic solution
• ISO 13408 for aseptic processing validation

Typical usage ratio

• Concentration typically 0.3% w/v in finished eye drop solution
• Maintained at 3 mg/mL using buffered saline carrier
• Adjusted with sodium chloride, EDTA, and benzalkonium chloride (as suitable)
• Viscosity adjusted with hypromellose or PVA if required

Downstream process integration

• Dissolution at ambient or cooled temperatures with controlled mixing
• Filter sterilization under HEPA-filtered environments
• Filling into presterilized ophthalmic dropper bottles by fully automated lines
• Labeling and serialized packaging for controlled distribution

Final product types

• Sterile single-use eye drop units
• Multi-use preservative-containing ophthalmic vials
• Hospital-use ophthalmic kits for bacterial conjunctivitis
• Bulk solution for contract filling partners

4. Veterinary Injectable and Oral Formulations

Veterinary pharmaceutical companies use our pharmaceutical-grade Gatifloxacin Hydrochloride in compounded injectable and oral formulations for livestock, poultry, and companion animals. The integration process includes accurate weighing for volumetric dosing, blending with carrier solutions or solid excipients, and rigorous batch release in line with veterinary pharmacopeia requirements, ensuring cross-species safety, stability, and residue compliance for food animals.

Industry compliance standards

• European Pharmacopoeia (Ph. Eur.) for veterinary products
• VICH GL18 and GL27 for veterinary drug residue and stability
• US FDA CVM Guidance for Industry #61
• Chinese Veterinary Pharmacopoeia

Typical usage ratio

• Varies from 10–20 mg/kg body weight (formulation strength)
• Injection: 5–10 mg/mL depending on species and indication
• Oral solutions: 10–50 mg/mL for dosing flexibility
• Powders: 1–5% API within the premix for feed additive

Downstream process integration

• Weighing and dispersing into veterinary-grade solvents or solid carriers
• Emulsification or granulation as per animal health formulations
• Filling into sterile vials or unit-dose sachets for field use
• Final residue analysis to ensure meat and milk withdrawal compliance

Final product types

• Veterinary injectable solutions (multi-species)
• Oral drench or soluble powder for water or feed administration
• Premix blends for industrial feed mills
• Bulk containers for contract veterinary compounding

5. Active Pharmaceutical Ingredient (API) Supply for Global Generic Manufacturing

As an API manufacturer, we fulfill large-volume supply contracts for regulated generic drug producers across several export markets. Materials are supported by full COA, DMF, and regulatory documentation, ensuring downstream formulators can integrate the API into new molecular entities, combination therapies, or regional final dosage forms in accordance with local submission and approval frameworks.

Industry compliance standards

• US FDA Drug Master File (DMF) submission requirements
• EU EMA CEP (Certificate of Suitability) for API
• WHO prequalification for international procurement
• Good Manufacturing Practice (GMP) per ICH Q7

Typical usage ratio

• Depends on downstream finished dosage strength: varies from 1% to 40% by blend weight
• Bulk shipments supplied in 25–50 kg packaging
• Customized micronization or granule size as per formulation requirements
• API supplied with defined impurity profile per batch

Downstream process integration

• Direct API receipt into blending and granulation areas
• Inspection and in-house analytical confirmation prior to release to production
• Integration with local excipients, binding agents, and dissolution enhancers
• Usage as standalone API or co-formulation with partner actives

Final product types

• Finished generic tablets, capsules, and IV solutions
• Partner-branded generic ophthalmic and oral products
• Contract manufactured finished goods for multinational distribution
• Custom API blends for regional regulatory submissions